Journal of Crohn's & colitis
-
Multicenter Study Observational Study
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Ustekinumab [UST] was recently approved in Europe for the treatment of moderate to severe Crohn's disease [CD]. Long-term real-world data are currently scarce for CD patients previously exposed to several biologics. ⋯ This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast.